3.64
0.27%
-0.010
Genfit ADR stock is currently priced at $3.64, with a 24-hour trading volume of 153.
It has seen a -0.27% decreased in the last 24 hours and a -2.77% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.63 pivot point. If it approaches the $3.67 resistance level, significant changes may occur.
Genfit ADR Stock (GNFT) Financials Data
There is no financial data for Genfit ADR (GNFT). Check out other stocks for more information.
Genfit ADR Stock (GNFT) Latest News
GENFIT Announces Revenues and Cash Position as of December 31, 2023
GlobeNewswire Inc.
GENFIT Announces 2024 Financial Calendar
GlobeNewswire Inc.
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
GlobeNewswire Inc.
GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)
GlobeNewswire Inc.
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
GlobeNewswire Inc.
GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials
GlobeNewswire Inc.
About Genfit ADR
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic test for the identification of patients with NASH; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.
Cap:
|
Volume (24h):